Cardiovascular

These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.

In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.

In addition to sharing research related to disparities and inequities in the cardiometabolic space, Rashon Lane, PhD, MA, Sutter Health, discussed “how we might need to think differently about how we are intervening on disparities.”

Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.

Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.

For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.

This expansion applies to the estimated 70 million patients who need either primary or secondary prevention, regardless of statin use.

Once-daily aprocitentan (Tryvio) is the first and only FDA-approved endothelin receptor antagonist for treating high blood pressure that remains uncontrolled despite other antihypertensive treatments.

Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.

The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.

According to the authors, these improvements may be part of the reason why there was a lower rate of major adverse cardiovascular events in the REPRIEVE study.

Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.

Although the prevalence of myocardial infarction (MI) was doubled among men compared with women with homozygous familial hypercholesterolemia (HoFH), both sexes had similar ages at first MI.

Light-to-moderate alcohol consumption seemed to provide greater protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status (SES) compared with those with lower SES, likely due to gaps in access to necessary care.

However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and became statistically insignificant after adjusting for cumulative past LDL-C exposure.

Elevated serum vitamin B12 concentration was positively associated with all-cause mortality risk, particularly among older adults, with concentrations exceeding 400 pmol/L showing significantly higher mortality rates.

This article compares cardiovascular disease risk management in community clinics during the COVID-19 pandemic among patients for whom primary care was delivered mostly in person vs mostly virtually.

Compared with in-person appointments, virtual care appointments were associated with higher completion rates, shorter time to appointment, increased hemoglobin A1c documentation, and decreased blood pressure documentation.

Findings from PREVENT-HF put to rest the idea that once remodeling in the heart's structure starts following anthracyclines that nothing can be done to treat it.

Two major trials presented at the European Society of Cardiology (ESC) 2023 Congress were the STEP-HFpEF and FRAIL-AF trials.

The top 5 most-viewed content from the American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Stephen Nicholls, PhD, MBBS, and Emelia J. Benjamin, MD, ScM, as well as coverage on multiple areas of cardiovascular medicine.

Our most-viewed cardiovascular content includes research showing that a heart-healthy diet lowers cardiovascular disease risk by 30%; an interview with Stephen Nicholls, PhD, MBBS, on the SURPASS-CVOT trial; and more.

Our top coverage from the 72nd American College of Cardiology (ACC) Scientific Session included results from the STELLAR, CLEAR Outcomes, ACCESS, and HALO trials.

Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.